Razelle Kurzrock Selected Research

siltuximab

7/2020	Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy.
3/2020	Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials.
1/2017	JAK1 Genomic Alteration Associated With Exceptional Response to Siltuximab in Cutaneous Castleman Disease.
1/2016	Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease.
10/2015	A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.
2/2015	Castleman's disease and sarcoidosis, a rare association resulting in a "mixed" response: a case report.
4/2014	A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.
7/2013	A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
8/2010	Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Razelle Kurzrock Research Topics

Disease

388	Neoplasms (Cancer) 06/2022 - 01/2002
30	Neoplasm Metastasis (Metastasis) 03/2021 - 08/2004
30	Fatigue 01/2021 - 02/2004
25	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 11/2008
22	Thrombocytopenia (Thrombopenia) 01/2020 - 02/2004
21	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 08/2004
21	Breast Neoplasms (Breast Cancer) 01/2022 - 06/2007
21	Melanoma (Melanoma, Malignant) 01/2021 - 08/2005
20	Pancreatic Neoplasms (Pancreatic Cancer) 01/2021 - 11/2004
15	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 03/2011
14	Diarrhea 01/2021 - 01/2008
14	Nausea 03/2020 - 10/2002
13	Carcinoma (Carcinomatosis) 01/2021 - 03/2008
13	Lung Neoplasms (Lung Cancer) 01/2021 - 12/2007
12	Castleman Disease (Castleman's Disease) 07/2020 - 09/2007
12	Neutropenia 03/2020 - 11/2010
12	Hypertension (High Blood Pressure) 03/2020 - 01/2010
11	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 10/2010
10	Hematologic Neoplasms (Hematological Malignancy) 12/2014 - 01/2002
10	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 10/2008 - 07/2002
9	Renal Cell Carcinoma (Grawitz Tumor) 10/2020 - 02/2002
9	Exanthema (Rash) 01/2020 - 04/2004
9	Mucositis 10/2016 - 07/2006
8	Adenocarcinoma 01/2021 - 12/2009
8	Fever (Fevers) 07/2020 - 10/2003
8	Ewing Sarcoma (Sarcoma, Ewing) 07/2020 - 04/2010
8	Infections 07/2020 - 01/2002
8	Disease Progression 03/2020 - 07/2008
8	Hepatocellular Carcinoma (Hepatoma) 10/2019 - 11/2009
8	Leukemia 01/2008 - 07/2002
7	Sarcoma (Soft Tissue Sarcoma) 01/2022 - 05/2007
7	Hodgkin Disease (Hodgkin's Disease) 11/2020 - 02/2004
7	Lymphoma (Lymphomas) 11/2018 - 02/2004
6	Anemia 01/2021 - 02/2011
6	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2015 - 06/2008
6	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2014 - 10/2002
5	Microsatellite Instability 01/2022 - 01/2017
5	Hypoxia (Hypoxemia) 01/2021 - 06/2009

Drug/Important Bio-Agent (IBA)

52	Biomarkers (Surrogate Marker)IBA 01/2022 - 09/2008
51	Pharmaceutical PreparationsIBA 01/2022 - 01/2002
33	Bevacizumab (Avastin)FDA Link 01/2020 - 01/2010
30	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2020 - 12/2004
28	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 06/2009
27	Circulating Tumor DNAIBA 01/2022 - 11/2016
27	Biological ProductsIBA 06/2020 - 07/2002
24	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2017
24	Proteins (Proteins, Gene)FDA Link 01/2022 - 09/2002
22	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2021 - 01/2011
19	Interleukin-6 (Interleukin 6)IBA 07/2020 - 02/2002
16	CytokinesIBA 07/2020 - 08/2002
15	Cell-Free Nucleic AcidsIBA 01/2022 - 01/2016
15	Monoclonal AntibodiesIBA 11/2020 - 08/2004
15	temsirolimus FDA Link 10/2017 - 04/2011
14	ErbB Receptors (EGF Receptor)IBA 01/2022 - 07/2008
14	Phosphotransferases (Kinase)IBA 01/2018 - 05/2007
14	CurcuminIBA 04/2016 - 11/2004
13	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2011 - 08/2002
12	RNA (Ribonucleic Acid)IBA 01/2022 - 05/2006
11	NivolumabIBA 01/2022 - 01/2016
11	PlatinumIBA 12/2021 - 04/2011
11	AntibodiesIBA 07/2020 - 12/2006
11	Oxaliplatin (Eloxatin)FDA LinkGeneric 08/2015 - 04/2007
11	tipifarnib (R115777)IBA 04/2011 - 07/2002
10	LigandsIBA 01/2020 - 09/2006
10	Interleukin-8 (Interleukin 8)IBA 08/2013 - 11/2004
10	Farnesyltranstransferase (Farnesyltransferase)IBA 04/2011 - 07/2002
9	Antineoplastic Agents (Antineoplastics)IBA 03/2021 - 05/2007
9	siltuximabIBA 07/2020 - 08/2010
9	Tyrosine Kinase InhibitorsIBA 01/2020 - 01/2005
8	Cetuximab (Erbitux)FDA Link 01/2022 - 02/2011
8	trametinibIBA 01/2021 - 08/2012
8	Paclitaxel (Taxol)FDA LinkGeneric 01/2019 - 12/2006
8	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2019 - 05/2008
8	Sorafenib (BAY 43-9006)FDA Link 02/2015 - 05/2008
8	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 02/2014 - 02/2002
8	NF-kappa B (NF-kB)IBA 12/2009 - 11/2004
7	Everolimus FDA Link 04/2021 - 11/2013
7	Trastuzumab (Herceptin)FDA Link 01/2021 - 03/2014
7	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2021 - 03/2009
7	MTOR InhibitorsIBA 11/2020 - 03/2012
7	EnzymesIBA 01/2019 - 11/2004
7	Carboplatin (JM8)FDA LinkGeneric 01/2019 - 04/2011
7	Imatinib Mesylate (Gleevec)FDA Link 07/2014 - 08/2006
7	Fluorouracil (Carac)FDA LinkGeneric 02/2013 - 08/2004
6	Lipase (Acid Lipase)FDA Link 01/2020 - 12/2010
6	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2020 - 07/2008
6	Interferon-alpha (Interferon Alfa)IBA 01/2020 - 01/2002
6	TOR Serine-Threonine KinasesIBA 07/2015 - 08/2010
5	IpilimumabIBA 01/2022 - 01/2020
5	Messenger RNA (mRNA)IBA 01/2022 - 10/2011
5	Aurora Kinase AIBA 12/2021 - 12/2014
5	Hormones (Hormone)IBA 11/2021 - 09/2008
5	CreatinineIBA 03/2021 - 10/2008
5	CyclinsIBA 01/2021 - 02/2015
5	Histone Deacetylase InhibitorsIBA 11/2020 - 06/2009

Therapy/Procedure

214	Therapeutics 03/2022 - 01/2002
39	Drug Therapy (Chemotherapy) 06/2022 - 01/2002
38	Immunotherapy 01/2022 - 04/2015
19	Precision Medicine 01/2022 - 09/2011
6	Drug Tapering 01/2019 - 04/2004